Results 211 to 220 of about 40,738 (244)

The potentiation of menadione on imatinib by downregulation of ABCB1 expression

Clinical and Experimental Pharmacology and Physiology, 2020
Abstract Imatinib was the first BCR‐ABL inhibitor used in clinical practice to treat chronic myeloid leukaemia (CML) and significantly improve the life expectancy of CML patients in the chronic phase. However, a portion of CML patients are resistant to imatinib.
Fei‐Yan Xiao, Fang‐Jiao Zhou, Fang Yuan, Wei Kuang, Gan Zhou, Hong‐Hao Zhou, Shan Cao   +6 more
openaire   +2 more sources

Genetic modulation of ABCB1: Sunvozertinib reverses ABCB1-mediated multidrug resistance in cancer cells

Cancer Genetics
Sunvozertinib is an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) designed to treat non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations under a phase II clinical trial. In this study, we investigated whether sunvozertinib could antagonize ABCB1, also known as multidrug ...
Lu-Qi Cao, Yuhao Xie, Xuanyu Chen, Harsh Patel, Luoxi Yuan, John Wurpel, Kunxiang Gong, Zhe-Sheng Chen   +7 more
openaire   +2 more sources

Membrane Assays to Characterize Interaction of Drugs with ABCB1 [PDF]

The Journal of Membrane Biology, 2015
ATP-binding cassette sub-family B member 1 (ABCB1) [P-glycoprotein (P-gp), multidrug resistance protein 1 (MDR1)] can affect the pharmacokinetics, safety, and efficacy of drugs making it important to identify compounds that interact with ABCB1. The ATPase assay and vesicular transport (VT) assay are membrane based assays that can be used to measure the
Zsolt, Fekete, Zsuzsanna, Rajnai, Tünde, Nagy, Katalin Tauberné, Jakab, Anita, Kurunczi, Katalin, Gémes, Krisztina, Herédi-Szabó, Ferenc, Fülöp, Gábor K, Tóth, Maciej, Czerwinski, Greg, Loewen, Peter, Krajcsi   +11 more
openaire   +3 more sources

Irinotecan and temozolomide brain distribution: a focus on ABCB1

Cancer Chemotherapy and Pharmacology, 2014
Glioblastoma (GBM), the most common primary brain tumor in adults, is usually rapidly fatal with median survival duration of only 15 months and a 3-year survival rate of
Lauriane, Goldwirt, Kevin, Beccaria, Alexandre, Carpentier, Robert, Farinotti, Christine, Fernandez   +4 more
openaire   +2 more sources

The influence of ABCB1 polymorphism C3435T on the pharmacokinetics of silibinin

Journal of Clinical Pharmacy and Therapeutics, 2015
Silibinin (Silybin), a major constituent of the milk thistle, is commonly used to treat chronic liver disease in some countries. It has been reported to inhibit the transport activity of ABCB1. This study was carried out to determine whether ABCB1 C3435T polymorphism influenced the pharmacokinetics of silibinin contained in silymarin capsules.Twenty ...
Z R, Tan, Y X, Zhou, J, Liu, W H, Huang, Y, Chen, Y C, Wang, L S, Wang   +6 more
openaire   +2 more sources

Promoter polymorphisms and allelic imbalance in ABCB1 expression

Pharmacogenetics and Genomics, 2007
The ABCB1 (MDR1) gene, encoding the transporter P-glycoprotein, is known to act on a broad range of prescription medicines. For this reason a large number of studies have assessed the functional consequences of variation in this gene. Particular attention has focused on the ABCB1_3435C>T polymorphism, an exonic variant resulting in a synonymous change.
Loeuillet, C, Weale, M, Deutsch, S, Rotger, M, Soranzo, N, Wyniger, J, Lettre, G, Dupre, Y, Thuillard, D, Beckmann, JS, Antonarakis, SE, Goldstein, DB, Telenti, A   +12 more
openaire   +5 more sources

Genetic Polymorphisms in ABCB1 Influence the Pharmacodynamics of Tacrolimus

Therapeutic Drug Monitoring, 2013
Tacrolimus has a large interindividual pharmacokinetic variability, and quantification of its effect is difficult. It is a substrate of ABCB1, an efflux pump expressed more on CD8 T cells than on CD4 T cells. The ABCB1 3435C>T single-nucleotide polymorphism (SNP) has been associated with interindividual differences in ABCB1 activity and may influence ...
Vafadari, Ramin, Bouamar, Rachida, Hesselink, Dennis, Kraaijeveld, Rens, van Schaik, Ron, Weimar, Willem, Baan, Carla, Gelder, Teun   +7 more
openaire   +2 more sources

Clinical Aspects of the MDR1 (ABCB1) Gene Polymorphism

Therapeutic Drug Monitoring, 2004
Transporter proteins, in particular P-glycoprotein (Pgp), are important determinants in absorption, tissue targeting, and elimination of drugs. In addition to physiological and environmental factors, its expression and function are modified by genetic polymorphisms of the MDR1 gene.
Michel, Eichelbaum, Martin F, Fromm, Matthias, Schwab   +2 more
openaire   +2 more sources

Association of a polymorphism in the ABCB1 gene with Parkinson's disease

Parkinsonism & Related Disorders, 2009
The ATP-binding cassette, sub-family B, member 1 (ABCB1) gene encoding the protein P-glycoprotein (P-gp) has been implicated in the pathophysiology of Parkinson's disease (PD) due to its role in regulating transport of endogenous molecules and exogenous toxins.
Marie, Westerlund, Andrea Carmine, Belin, Anna, Anvret, Anna, Håkansson, Hans, Nissbrandt, Charlotta, Lind, Olof, Sydow, Lars, Olson, Dagmar, Galter   +8 more
openaire   +2 more sources

ABCB1 single nucleotide polymorphisms in the Brazilian population

Molecular Biology Reports, 2009
The ABCB1/MDR-1 gene, which encodes P-glycoprotein, is highly polymorphic. We analyzed 278 healthy Brazilian individuals through PCR-RFLP to identify ABCB1 variants and determine the genotypic and allelic frequencies. Genotypic frequencies for C1236T (rs1128503) were 0.31 for CC, 0.60 for CT and 0.09 for TT and allelic frequencies were 0.61 and 0.39 ...
Marcos Antonio Mauricio, Scheiner, Arthur Motta, Damasceno, Raquel Ciuvalschi, Maia   +2 more
openaire   +2 more sources